Zealand Pharma A/S (OTCMKTS:ZLDPF) Trading Up 5.5% – Should You Buy?

Zealand Pharma A/S (OTCMKTS:ZLDPF) shares shot up 5.5% during mid-day trading on Thursday . The company traded as high as $83.12 and last traded at $83.12. 170 shares traded hands during trading, a decline of 78% from the average session volume of 782 shares. The stock had previously closed at $78.7776.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on ZLDPF shares. Zacks Research upgraded shares of Zealand Pharma A/S from a “strong sell” rating to a “hold” rating in a research report on Monday, September 15th. Wells Fargo & Company upgraded shares of Zealand Pharma A/S to a “strong-buy” rating in a research report on Thursday, July 24th. Five equities research analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the company has an average rating of “Strong Buy”.

Zealand Pharma A/S Stock Performance

The stock’s 50 day moving average is $73.80 and its 200 day moving average is $66.12. The firm has a market cap of $5.90 billion, a price-to-earnings ratio of 5.84 and a beta of 0.71. The company has a current ratio of 15.09, a quick ratio of 15.08 and a debt-to-equity ratio of 0.02.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last posted its earnings results on Thursday, November 13th. The company reported ($0.90) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.11) by $0.21. Zealand Pharma A/S had a return on equity of 67.06% and a net margin of 73.90%.The company had revenue of $7.76 million during the quarter, compared to the consensus estimate of $4.54 million. Analysts anticipate that Zealand Pharma A/S will post -2.19 earnings per share for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.